<DOC>
	<DOCNO>NCT02990286</DOCNO>
	<brief_summary>The purpose study evaluate efficacy lung function 6 month one course rituximab ( 2 infusion ) mycophénolate mofétil ( MMF ) treatment compare one course placebo 6 month MMF treatment broad range ILD patient non-responders first line immunosuppressive treatment .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Rituximab With Mycophenolate Mofetil Patients With Interstitial Lung Diseases</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . A diagnosis ILD : ILD associate differentiated CTD IPAF ( base internationally accepted criterion ) OR idiopathic ILD 3 . A diagnosis NSIP base : histological pattern NSIP OR HRCT finding suggestive NSIP define basal predominant reticular abnormality traction bronchiectasis , peribronchovascular extension subpleural sparing , frequently associate groundglass attenuation 4 . Patients respond relapse able continue least one firstline immunosuppressive treatment ILD : corticosteroid , azathioprine , cyclophosphamide immunosuppressant . For assessment clinical response , absence response define : either decrease increase , &lt; 10 % % predicted FVC . 5 . Subjects cover right French social security ( include CMU ) , 6 . Written inform consent obtain subject , specific check box Consent form study , understand risk men woman treat mycophenolate mofetil . And additional write consent subject care contraception agreement form woman childbearing potential treated mycophenolate . 7 . Ability subject comply requirement study 1 . Known diagnosis significant respiratory disorder ( asthma , tuberculosis , sarcoidosis , aspergillosis , cystic fibrosis ) CTDNSIP , IPAFNSIP iNSIP 2 . Evidence clinically significant , severe unstable , acute chronically progressive cardiac ( severe heart failure New York Heart Association Class IV severe uncontrolled cardiac disease ) , medical disease ( NSIP ) surgical disorder , condition may affect patient safety judgment investigator . 3 . HRCT pattern typical usual interstitial pneumonia ( UIP ) 4 . For patient idiopathic ILD , HRCT pattern possible UIP ( evocative NSIP ) 5 . Histological pattern pattern NSIP 6 . A first line treatment MMF rituximab 7 . Known hypersensitivity MMF rituximab sulfonamide antibiotic 8 . Treatment immunosuppressive treatment corticosteroid : azathioprine , cyclophosphamide , methotrexate , cyclosporine , tacrolimus , leflunomide within 2 week ( 5 halflives &lt; = 2 week ) prior inclusion intravenous immunoglobulin , hydroxychloroquine monoclonal antibody therapy ( limited etanercept , adalimumab , efalizumab , infliximab , golimumab , certolizumab ) within 6 month ( 5 halflives &lt; = 6 month ) prior inclusion 9 . Patients register pulmonary transplantation list 10 . Patients know hypoxanthineguanine phosphoribosyltransferase ( HGPRT ) hereditary deficiency ( LeschNyhan KelleySeegmiller syndrome ) 11 . Pregnant breastfeed woman , woman childbearing potential use two reliable contraceptive method ( include female partner sexually active men treat mycophenolate ) men use contraceptive method ( condom ) , woman men pregnancy project year follow randomization . 12 . Patients significant risk infectious complication : HIV positive , known immunodeficiency syndrome , untreated tuberculosis , hepatitis B C know viral infection , infection require antiinfectious treatment precede 4 week 13 . Current history substance and/or alcohol abuse 14 . Deprivation liberty , judicial protection 15 . Participation another biomedical research experimental drug medical device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non specific intertitial pneumonia</keyword>
	<keyword>interstitial pneumonia autoimmune feature</keyword>
	<keyword>connective tissue disease</keyword>
	<keyword>rituximab</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>pulmonary fibrosis</keyword>
</DOC>